Skip to main content

Antisense Circular RNA as Therapeutic Compound for Treatment of Covid-19

Ref-Nr: TA-TM 1110


A new artificial circular RNA prevents SARS coronavirus 2 (SARS-CoV-2) from replicating in infected cells.


The new SARS-CoV-2 has made the disease Covid-19 a pandemic with effects on all aspects of human life by spreading rapidly across the whole world. Despite the immense progress in the treatment of Covid-19 patients in recent months, there is an urgent need for effective and well-tolerated therapeutic options, alternatively to the current mRNA-based and other vaccination strategies.

Bilder & Videos


The new circular RNA enables specific binding and inhibition of SARS coronavirus 2 and thus opens up new therapeutic approaches for the treatment of Covid-19. This mechanism of action can effectively prevent and treat infections with SARS-CoV-2.


  • The new circular RNA is much more stable than the corresponding linear RNA.
  • Circular RNA is designed to bind specifically to sequence-conserved regions of SARS-CoV-2 genome and subgenomic RNAs.
  • Circular RNA can easily be synthesized in preparative amounts and introduced into cells.


  • Therapy of Covid-19
  • Early prevention of infections by SARS-CoV-2
  • Post-exposure prophylaxis (PEP) after contact with Covid-19 patients


On behalf of its shareholder Justus-Liebig-Universität Giessen TransMIT GmbH is looking for cooperation partners or licensees for further development in Germany, Europe, US, and Asia.

TransMIT Gesellschaft für Technologietransfer mbH

Anouschka Ulherr
0641 946434

Kerkrader Str. 3
35394 Gießen




  • EP anhängig


Circular RNA, Covid-19, Therapy, Coronavirus, Compound, Post-exposure Prophylaxis, SARS-CoV-2

Angebot Anbieter-Website

Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen